DOSE RESPONSE STUDY OF BG9273 IN MODERATE TO SEVERE PLAQUE PSORIASIS

BG9273是一种重组蛋白，通过与CD2受体的相互作用来调节免疫反应。BG9273与CD2的相互作用已被证明能抑制体外人T淋巴细胞反应，因此有可能成为治疗银屑病的有效药物。临床前和临床数据表明，BG9723的剂量应该是安全且耐受性良好的。025毫克/公斤至。每周150 mg/kg，连续12周。该研究是一项多中心、随机、双盲、安慰剂对照、平行组剂量反应研究，比较了BG9273在中度至重度斑块性银屑病患者中的三种剂量水平。所有受试者年龄在18至70岁之间，患有中度至重度斑块性银屑病，体表受累率在10%或以上。研究的主要目的是确定每周给药1次、总共12次的BG9273的剂量和血药浓度与临床反应的关系。

BG9273 is a recombinant protein that has been designed to modulate immune responses through interaction with the CD2 receptor. The interaction of BG9273 with CD2 has been shown to inhibit in vitro human T lymphocyte responses, and therefore has potential as an effective therapy for psoriasis. Pre-clinical and clinical data suggest that BG9723 should be safe and well tolerated at dosing of .025 mg/kg to .150 mg/kg weekly for 12 weeks. This study was a multicenter, randomized, double-blind placebo-controlled, parallel-group dose response study comparing three dose levels of BG9273 in subjects with moderate to severe plaque psoriasis. All subjects were between 18 and 70, with moderate to severe plaque psoriasis and a body surface involvement of 10% or greater. The primary study objective was to determine the relationship of clinical response to the dose and plasma concentration of BG9273 when administered once a week for a total of up to 12 doses.